

# Cluster of Differentiation-44 as a Novel Biomarker of Lupus Nephritis and Its Role in Kidney Inflammation and Fibrosis

Caleb CY Wong,<sup>1†</sup> Lucy Y Gao,<sup>1†</sup> Yuesong Xu,<sup>1</sup> Mel KM Chau,<sup>1</sup> Danting Zhang,<sup>1</sup> Desmond YH Yap,<sup>1</sup> Shirley KY Ying,<sup>2</sup> Cheuk Kwong Lee,<sup>3</sup> Susan Yung,<sup>1\*</sup> Tak Mao Chan,<sup>1\*</sup>


<sup>1</sup>Department of Medicine, School of Clinical Medicine, the University of Hong Kong, Hong Kong

<sup>2</sup>Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong

<sup>3</sup>Hong Kong Red Cross Blood Transfusion Service, Hong Kong

<sup>†</sup>These authors contributed equally to this work and share first authorship.

## Supplementary Material



### Supplementary Figure 1. Purification of anti-CD44 antibody and its effect on proteinuria

(A) Anti-CD44 monoclonal antibody was purified from the supernatant of rat B cell hybridomas (clone IM7.8.1) by protein G-Sepharose chromatography using HiTrap® Protein G High Performance columns followed by Pierce™ High Capacity Endotoxin Removal Spin Columns. The purity of the antibody was assessed by SDS-PAGE under reducing conditions using 30 μg total protein per lane. Purified IM7.8.1 antibody showed 2 bands at 25 kDa and 50 kDa representing the light and heavy chains of IgG respectively. BD Pharmingen™ purified NA/LE rat IgG2b,κ isotype control was also electrophoresed for comparison. (B) Preliminary studies showing the effect of weekly tail vein administration of Control IgG (10 or 20 μg, n = 4) or anti-CD44 antibody (10 or 20 μg, n = 5) on weekly urine ACR for 4 weeks (\* $P < 0.05$ , compared to baseline (T = 0)).